Clinical and biological characteristics of SpA and TA and treatments (n = 14).
| Pt | Age at SpA DX, yrs | SpA Subtype | SI per mNY Criteria | SI per ASAS Criteria | HLA-B27 | Age at TA DX, yrs | Imaging Evidence of Vessel Narrowing, Thickening, or Occlusion | CRP, mg/l | NSAID | DMARD | Anti-TNF | Vascular Surgery |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 26 | P SpA | ND | 1 | 1 | 26 | 1 | 25 | 1 | SSZ | 1 | 0 |
| 2 | 20 | axSpA | 1 | ND | ND | 41 | 1 | 88 | 1 | MTX | 0 | 0 |
| 3 | 31 | axSpA | 1 | 0 | 1 | 41 | 1 | 13 | 1 | MTX | 1 | 0 |
| 4 | 19 | P SpA w/ psoriasis | ND | ND | 0 | 35 | 1 | 15 | 1 | SSZ | 0 | 1 |
| 5 | 31 | SAPHO | ND | 0 | ND | 38 | 1 | 180 | 1 | MTX | 1 | 1 |
| 6 | 50 | P SpA w/ psoriasis | 1 | 1 | 0 | 53 | 1 | 32 | 1 | MTX | 0 | 1 |
| 7 | 63 | axSPA and P SpA | 1 | 0 | 0 | 64 | 1 | 90 | 1 | 0 | 0 | 0 |
| 8 | 53 | axSpA | 1 | 0 | 0 | 56 | 1 | 86 | 1 | MTX | 1 | 0 |
| 9 | 57 | axSpA | ND | 1 | 0 | 59 | 1 | 12.5 | 1 | SSZ | 0 | 0 |
| 10 | 23 | axSpA | 0 | 1 | 1 | 20 | 1 | 29 | 1 | MTX | 1 | 0 |
| 11 | 51 | axSpA | 0 | 1 | 0 | 58 | 1 | 150 | 1 | 0 | 1 | 0 |
| 12 | 52 | axSpA and P SpA | 1 | 0 | 0 | 55 | 1 | 86 | 0 | 0 | 0 | 0 |
| 13 | 37 | axSpA and P SpA | 0 | 1 | 0 | 44 | 1 | 6 | 1 | 0 | 1 | 1 |
| 14 | 57 | axSpA | ND | 1 | 0 | 63 | 1 | 250 | 1 | MTX | 0 | 0 |
SpA: spondyloarthritis; TA: Takayasu arteritis; Pt: patient; DX: diagnosis; P SpA: peripheral SpA; axSpA: axial SpA; mNY criteria: modified New York criteria; ASAS: Assessment of Spondyloarthritis international Society criteria; CRP: C-reactive protein; NSAID: nonsteroidal antiinflammatory drugs; DMARD: disease-modifying antirheumatic drugs; anti-TNF: anti-tumor necrosis factor; SAPHO: synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome; MTX: methotrexate; SSZ: sulfasalazine; SI: sacroiliitis; ND: no data.